Announcement
NeuroSearch announces revised financial calendar for 2008
The date for the announcement of the NeuroSearch 2007 annual report has been
changed from 5 March to 4 March and the NeuroSearch financial calendar for 2008
is therefore now as follows:
4 March 2008: 2007 annual report
30 April 2008: Annual general meeting and first quarter 2008 report
27 August 2008: 2008 half year report
19 November 2008: Third quarter 2008 report
Asger Aamund
Chairman of the Board
Contact persons:
Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4460 8212 or +45 4017 5103
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, NS1209 in epilepsy/pain (Phase II), ABT-894 in ADHD (Phase
II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia
(Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's
disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS
diseases - both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o.
(Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I).
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates
and holds equity interests in several biotech companies.
